What Tuberculosis Is and Why It Was Called Consumption
Tuberculosis (TB), once widely known as consumption, is a disease caused by infection with Mycobacterium tuberculosis. It most commonly affects the lungs but can spread to other parts of the body. TB spreads through airborne droplets when a person with active lung TB coughs, sneezes, or speaks. Historically called consumption because of the severe weight loss and wasting it caused, modern medicine has transformed TB from a frequently fatal illness into a treatable condition when diagnosed early and managed appropriately.
How Tuberculosis Is Transmitted
TB spreads when infectious droplets enter the air and are inhaled by another person. Transmission usually occurs in close, prolonged settings such as households, shelters, or workplaces with poor ventilation. People with latent TB infection are not contagious. TB is not spread by casual contact, sharing food or drink, or touching surfaces. Factors that increase transmission risk include crowded conditions, limited airflow, and delayed treatment of infectious cases.
Key Transmission Details
- Airborne route: inhalation of droplet nuclei containing bacteria
- Contagious period: symptom-driven treatment reduces infectiousness within weeks
- Environment matters: indoors, crowded, and poorly ventilated spaces elevate risk
Common Symptoms and Early Signs
Pulmonary TB symptoms often develop gradually and may include a persistent cough lasting more than two to three weeks, coughing up blood or sputum, chest pain, unexplained weight loss, fatigue, fever, and night sweats. Extrapulmonary TB can affect lymph nodes, bones, the brain, or other organs, leading to site-specific signs such as swollen lymph nodes, back pain, or neurological changes. Recognizing these symptoms early helps prevent progression and reduces the chance of transmitting TB to others.
Diagnosis and Testing Methods
TB diagnosis combines clinical evaluation, imaging, and laboratory tests. For pulmonary TB, health care providers may use a tuberculin skin test (TST) or an interferon-gamma release assay (IGRA) to detect infection. Sputum tests, including smear microscopy and nucleic acid amplification tests (NAATs) like PCR, identify whether TB bacteria are present and whether they respond to key drugs. Chest X-rays and CT scans help identify lung abnormalities. Testing for drug resistance guides treatment choices and improves outcomes.
Diagnostic Tool Overview
| Test or Metric | Verified Detail | Source Type |
|---|---|---|
| Tuberculin Skin Test (TST) | Measures immune response to TB protein; used to screen for latent infection | Guideline (CDC/WHO) |
| NAAT (e.g., Xpert MTB/RIF) | Detects TB DNA and rifampicin resistance quickly; recommended for initial testing | Guideline (WHO/CDC) |
| Sputum Smear and Culture | Culture confirms viability and species; used for drug susceptibility testing | Laboratory reference |
| Chest X-ray | Identifies lung patterns suggestive of active TB; often used alongside microbiology | Clinical practice |
| Drug Susceptibility Testing (DST) | Determines which antibiotics are effective; critical for treatment planning | Laboratory reference |
Treatment and Standard Therapy
TB is curable with appropriate antibiotics. Standard treatment for drug-susceptible pulmonary TB involves an initial intensive phase with isoniazid, rifampin, ethambutol, and pyrazinamide, followed by a continuation phase with isoniazid and rifampin for several months. For latent TB infection, shorter regimens such as isoniazid for several months or rifampin-based options are commonly used. Treatment for drug-resistant TB, including multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB), requires longer, more complex regimens with second-line drugs. Adherence support and directly observed therapy (DOT) improve cure rates and reduce the risk of relapse.
First-Line TB Drug Regimens at a Glance
| Condition | Typical Regimen (Duration) | Key Drugs |
|---|---|---|
| Drug-Susceptible Pulmonary TB | 2 months intensive + 4 months continuation (≈6 months total) | Isoniazid, Rifampin, Ethambutol, Pyrazinamide |
| Latent TB Infection (treatment to prevent active disease) | 3–4 months of rifampin alone or 9 months of isoniazid | Rifampin or Isoniazid |
| Multidrug-Resistant TB (MDR-TB) | 9–18 months or longer, depending on regimen and response | Fluoroquinolones, Bedaquiline, Linezolid, other second-line agents |
Prevention and Public Health Measures
Preventing TB involves identifying and treating infectious cases promptly, improving ventilation in high-risk settings, and screening high-risk groups. In areas with high TB burden, the BCG vaccine can offer partial protection, especially against severe forms of childhood TB. Reducing transmission also depends on social determinants such as housing, nutrition, and access to care. People with latent TB infection and a higher risk of progressing to active disease may receive preventive therapy to lower their lifetime risk of becoming ill.
When to Seek Medical Care
Consult a health care provider if you have a persistent cough lasting more than a few weeks, unexplained weight loss, prolonged fever, night sweats, or coughing up blood. Seek urgent care for severe symptoms such as difficulty breathing, chest pain, or signs of significant illness. If you have known exposure to TB or work in a high-risk setting, discuss screening with your provider. Early evaluation and treatment improve outcomes and reduce the chance of spreading TB to others.
Progress, Challenges, and Living with TB
Global efforts have reduced TB incidence and mortality, but challenges remain, including drug resistance, diagnostic delays, and inequitable access to care. People living with TB often face stigma, financial burden, and complex treatment schedules. Continued investment in testing, treatment, research, and social support is essential to sustain progress. Understanding TB as a treatable, preventable disease helps individuals and communities make informed decisions and protect public health over time.